## Assessment of the impact of the new blister packaging of Biktarvy<sup>®</sup> (B/F/TAF) on treatment satisfaction of people living with HIV

### **Authors**

Cruz JP<sup>1,2</sup>, Santos O<sup>3,4</sup>, Rodrigues M<sup>1</sup>, Morais R<sup>1</sup>, Borralho T<sup>1</sup>, Ferreira F<sup>1</sup>, Ferreira A<sup>5</sup>, Albuquerque J<sup>5,6</sup>, Nogueira P<sup>3</sup>, Silva MP<sup>7</sup>, and Antunes F<sup>3</sup>

1. Serviços Farmacêuticos da Unidade de Saúde Local Santa Maria, Lisboa, Portugal

2. iMed.ULisboa - Institute for Medicine Research, Faculdade de Farmácia, Universidade de Lisboa, Portugal

3. Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Portugal

4. Unbreakable Idea Research, Painho, Portugal

5. BlueClinical - Investigação e Desenvolvimento em Saúde, Lda, Porto, Portugal

6. Centro de Estatística e Aplicações, Faculdade de Ciências, Universidade de Lisboa, Portugal

7. Gilead Sciences, Lda, Lisboa, Portugal

#### Abstract 1

2 **Background:** Antiretroviral therapy (ART) is highly effective in people living with HIV

- 3 (PLHIV), but its success depends on treatment satisfaction and adherence. A determinant of
- 4 satisfaction regards how the medication is delivered to the patient, namely how it is
- 5 contained (e.g., bottles, blisters, etc). A new packaging of Biktarvy<sup>®</sup> has been introduced as

6 a monthly blister, aiming to improve satisfaction, facilitate traceability of daily medication,

7 portability, and discretion (reducing stigma associated with ART), and, ultimately, enhance

- 8 adherence.
- 9 Goals: The study's objective was to assess the impact of changing the packaging of
- 10 Biktarvy® (B/F/TAF) from a standard pill bottle to a monthly blister with a weekly calendar

11 on therapy satisfaction. Additionally, the association between treatment satisfaction and

12 selected patients' characteristics (e.g., ART duration) was evaluated. A secondary goal was

13 to characterize the association between the change of packaging on patient's adherence.

- 14 Methods: This is an observational longitudinal (retrospective and prospective) study with
- 15 patients following ART for at least six months (ambulatory clinical management) recruited
- 16 according to a non-probabilistic sequential sampling. Satisfaction was measured at two
- 17 different moments: at baseline, HIVTSOs were used to assess satisfaction within the
- 18 previous six months' use of medication containers (bottles). Six months later, patients filled
- 19 in the HIVTSQc to assess their perception of satisfaction change with the new packaging
- 20 (blister). Adherence was assessed by pharmacy medication dispensing at the hospital.
- Results: The study enrolled 105 patients in two selected centers (102 patients completed 21

22 the study). Patients were significantly more satisfied (HIVTSQc scores) with ART when

- 23 using the new Biktarvy® blister pack package. Importantly, gains of ART satisfaction were
- higher among those less satisfied with the bottle packaging. No significant associations 24
- 25 were found between HIVTSQc scores and sociodemographic or ART-related variables.
- 26 Keywords: PLHIV; Antiretroviral therapy; Patient satisfaction; Adherence
- 27

Introduction 28

- In the last decade, antiretroviral therapy (ART) has demonstrated high efficacy, resulting in 29
- 30 higher than 90% viral suppression rates. Therapeutic guidelines identify several regimens
- 31 that ta Hosprendio cranades how goder on warpper cossien cofficiental bearder to provide hould winge with a Hilly infrationatice.

- 32 (PLHIV), including single tablet coformulations<sup>1</sup>.
- 33 The success of ART depends on treatment satisfaction and adherence, which are impacted by
- 34 several factors, including medication usage facility, patient perception of results, and side
- effects. These factors must be considered when making treatment decisions in the clinical 35
- 36 management of PLHIV<sup>2</sup>. For all these reasons, satisfaction has been considered relevant in
- 37 the assessment and differentiation between therapeutic regimens, aiming to improve clinical
- 38 outcomes, the well-being of PLHIV, and maximizing improvement of health status<sup>3,4</sup>.
- 39 Medication packaging in blister packs, with a weekly calendar, has the potential to
- 40 contribute to improving adherence to ART and optimizing outcomes in the treatment of 41 PLHIV. In the scope of treatment of hypertension, patients with medication in blisters with
- 42 weekly calendars renewed their prescription more frequently, had higher Medication
- 43 Possession Ratio (MPR) and better control of blood pressure at 12 months<sup>5</sup>. Additionally, a
- 44 meta-analysis of 52 studies (n = 22.858) involving patients with different diseases showed
- 45 an increase in adherence from 63% to 71%, related to the change in the packaging of the
- 46 medication to blisters with calendars, which demonstrates a practical improvement in
- 47 treatment adherence because of this tablet package modification<sup>6</sup>.
- 48 Biktarvy® is indicated for the treatment of adults infected with human immunodeficiency
- 49 virus type 1 (HIV-1) without present or past evidence of viral resistance to the integrase
- 50 inhibitor class, emtricitabine or tenofovir. Currently, Biktarvy® new package contains the 51 same number of units (30 tablets), but packaged in four blisters of seven tablets, with a
- 52 weekly calendar, and one blister of two tablets. This new packaging has the potential for
- 53 the patient to improve the adherence to therapy, facilitating the traceability of daily
- 54 medication dosage, its portability and greater medication discretion, reducing the risk of 55 stigma associated with ART. In Portugal, there was a complete replacement of units of
- 56 Biktarvy® in bottles by Biktarvy® in blisters, until May 2022<sup>7</sup>.
  - 57 This project aimed to estimate the impact of the new Biktarvy® packaging containing the
- 58 same number of units (30 tablets), but packed in four blisters of seven tablets, with a weekly
- calendar, and one blister of two tablets, on patient's satisfaction (main outcome) and 59
- 60 adherence (secondary outcome) with ART.

#### Materials and methods 61

62

#### **Research strategies** 63

64 The study followed an observational retrospective/prospective design with PLHIV being

- 65 followed in two Portuguese hospitals. Data collected referred to a period of ART of at least
- six months before the change of packaging (bottle; retrospective data) and six months of 66
- 67 experience with the new packaging (blister; prospective data).
- 68 The study was conducted in accordance with the clinical study protocol (CSP), the
- 69 International Council for Harmonization, Good Clinical Practices, and the Declaration of
- 70 Helsinki, as well as the applicable European and Portuguese laws and regulations approved
- 71 by the Ethics Committee of the Centro Académico de Medicina de Lisboa (reference
- 72 number 226/22).
- 73 All patients signed a written informed consent form before entering the study. Each 74 participant received a full explanation of the project goals, procedures, and implied tasks
- 75 (and burden) from patients. Subjects were informed that their participation was voluntary
- 76 and assured that they could abandon the study at any time without any prejudice. They also
- 77 received a copy of the subject's information and, after being fully clarified, signed the
- 78 informed consent form.
- 79

#### 80 Sampling: inclusion and exclusion criteria

- 81 The sample size was planned to enroll 100 PLHIV (including at least 20 women) on 82 treatment with Biktarvy®, being over 18 years old, under ambulatory clinical management 83 in two Portuguese hospitals for at least six months and accepting to participate voluntarily
- 84 in the study.
- 85 Patients coming to the hospital pharmacy were included sequentially (non-probabilistic 86 sampling), and the sample size was determined to allow an estimate of the patients with 87 timely prescription delivery in the hospital pharmacy (before the time of prescription collection), with the precision of 7% to 10%. The first patient visit occurred in August 2022, 88
- 89 and the last patient visit occurred in December 2023.
- 90

#### 91 **Data collection and instruments**

- 92 Subjects' data was directly collected on paper-based clinical reports forms (CRFs). 93 Subsequently, data were transcribed into the study database by a data entry operator. Each 94 patient was given a study reference number, which was archived in the clinical file.
- 95 Data collected included demographic information (age, gender, nationality, level of 96 education), clinical and laboratory data (duration of ART, viral load, and CD4 T 97 lymphocytes count). For assessing satisfaction with ART, two instruments have been used: the Portuguese version of the HIV Treatment Satisfaction Questionnaires version "s" 98 99 (HIVTSQs), at baseline (retrospective assessment related to the previous six months), and 100 the Portuguese version for the HIV Treatment Satisfaction Questionnaires version "c"
- 101 (HIVTSQc), six months after starting the use of Biktarvy<sup>®</sup> monthly blisters. HIVTSQs and 102 HIVTSQc have been developed by Woodcock & Bradley, with evidence of sound

- 103 psychometric properties<sup>8,9</sup>. The HIVTSQs is composed of 10 items being answered in a
- 104 seven-points Likert-type scale (varying from 0 = "very dissatisfied" to 6 = "very satisfied").
- 105 The HIVTSQs provides a global score of satisfaction as well as scores for two
- 106 subdimensions: the HIVTSOs General Satisfaction/Clinical subscale and the HIVTSOs
- 107 Lifestyle/Ease subscale; the HIVTSQc also includes a subscale: the HIVTSQc General 108 Satisfaction/Clinical subscale.
- 109 Additionally, and for a better understanding of the factors of satisfaction with ART, patients
- 110 were asked about their level of agreement with four statements, both at baseline and at
- 111 follow-up: The packaging of this medication allows me to easily check if I've taken my daily
- 112 pill, This medicine comes in a package that lets me take the pill easily and
- 113 without anyone noticing. This medicine's packaging reminds me that I need to refill my
- 114 prescription, and I don't like the way this medicine is packaged. Finally, patients reported
- 115 their level of agreement with one more statement, at the follow-up moment: I am more
- 116 satisfied with this type of medication packaging than with the previous one, which was a
- 117 plastic bottle. Level of agreement was indicated through a 5-points Likert scale ranging
- 118 from l = totally disagree to 5 = totally agree.
- 119 To assess the impact of the new Biktarvy® packaging on adherence, pharmacy medication
- 120 dispensing was measured, more specifically, by registering the number of tablets supplied
- 121 in the last delivery per number of days elapsed since the last delivery. Pharmacy medication
- 122 dispensing data were collected by pharmacy records, and questionnaires were completed
- 123 while patients waited in the hospital pharmacy (a representation of the study design is
- 124 presented in Figure 1).
- 125

#### 126 Figure 1. Study design diagram

127

#### 128 Data analysis

- 129 The statistical analyses were conducted using R statistical software version 4.2.1. 130 Descriptive statistics were used to analyze results: percentages and absolute frequencies to 131 describe the categorical variables; minimum, maximum, interquartile range, means, 132 medians, and standard deviation for the quantitative variables.
- 133 All ten items from HIVTSQs were summed up to obtain a treatment satisfaction score (0 to
- 134 60), where higher scores represent greater satisfaction. The HIVTSQs General Satisfaction 135 / Clinical subscale includes the items 1, 2, 3, 9 and 10 (range: 0 to 30), and the HIVTSQs 136
- Lifestyle/Ease subscale includes the remaining items, namely the items 4, 5, 6, 7 and 8 137 (range: 0 to 30).
- 138 For the HIVTSQc, the sum of all items results in a treatment satisfaction (change) score
- 139 (range: -30 to 30), where positive values are associated with improvement in satisfaction
- 140 with treatment, the 0 score represents no change, and negative values indicate a 141 deterioration in treatment satisfaction. For the HIVTSQc General Satisfaction / Clinical
- 142 subscale and HIVTSQc Lifestyle/Ease subscale, the same items as in HIVTSQs subscales
- 143 were included (range: -15 to 15). Cronbach alpha was used to assess internal consistency
- 144 for both HIVTSQs and HIVTSQc, and correlations were applied to assess the convergent
- 145 validity between these two scales.
- 146 To evaluate the effect of switching the medication from a standard pill bottle to a monthly
- 147 blister in patient satisfaction, a unilateral Wilcoxon signed rank test was applied (alternative

medRxiv preprint doi: https://doi.org/10.1101/2024.10.26.24316182; this version posted October 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 148 hypothesis: pseudomedian > 0) to the score in the HIVTSQc scale and its subscales. 149 Differences between independent samples in the distribution of these scores was tested 150 using the Wilcoxon rank sum test.
- Linear regression models have been performed to assess the predictive effect of baseline 151
- 152 satisfaction on satisfaction change. The scores for HIVTSQc scale, HIVTSQc General 153 Satisfaction subscale, HIVTSQs Clinical subscale, e HIVTSQc Lifestyle/Ease subscale
- 154 were found as very skewed (left-skewed distribution). Therefore, their values were shifted 155 and reversed for modeling purposes, as follows: HIVTSQc scale recoded = 61 + 1 -
- 156 (*HIVTSOc scale* + 31); *HIVTSOc General Satisfaction / Clinical subscale* recoded = 31
- 157 + 1 - (HIVTSOc General Satisfaction / Clinical subscale + 16); HIVTSOc Lifestvle/Ease 158 subscale recoded = 31 + 1 - (HIVTSOc Lifestyle/Ease subscale + 16). Resulting scores were
- 159 log-transformed and included in the linear regression models as dependent variables. The
- 160 models included as predictors sex, age group, education, nationality, and antiretroviral
- 161 therapy duration, adjusting for the treatment satisfaction score at baseline. When studying
- 162 the predictive effect of treatment satisfaction at baseline (for HIVTSQs scale, HIVTSQs
- 163 General Satisfaction / Clinical subscale, and HIVTSQs Lifestyle/Ease subscale) on 164 HIVTSQc, HIVTSQc General Satisfaction / Clinical e HIVTSQc Lifestyle/Ease, simple
- 165 models (no additional variables, in these equations) have been used. The predictors
- 166 mentioned above were also included all-together in one model (M2). Estimates and 95%
- 167 confidence intervals (CI), and p-values are presented.
- 168 169

#### **Results** 170

171 One hundred and five PLHIV were enrolled in the study. Two were discontinued due to a 172 physician's decision to switch ART, and one had not completed six months of using

- 173 Biktarvy<sup>®</sup> in blisters by the end of the data collection process (therefore, not considered for
- 174 assessing satisfaction with the blister packaging). Table 1 summarizes the demographic and
- 175 clinical characteristics of participants at baseline.
- 176

#### 177 Table 1. Sociodemographic and clinical characteristics of the participants

aiada ahi

	n	105		
Sex, n (%)	Female, n (%)	22 (21.0)		
	Male, n (%)	83 (79.1)		
	n	105		
	Mean	43.35		
A go	SD	11.69		
Age	Mediana [Q1, Q3]	42.00 (34.00, 53.00)		
ge	Minimum	21		
	Maximum	79		
	n	105		
	No formal education	2 (1.9)		
Scholarship level, n (%)	Primary (basic) education	27 (25.7)		
	Secondary education	37 (35.2)		
	Superior education	39 (37.1)		
Nationality n (9/)	n	105		
Nationality, n (%)	Portuguese	59 (56.20)		

	Non-Portuguese	46 (43.8)
Clinical variables		
	n	105
	Less than 1 year	2 (1.9)
Antiretroviral therapy duration, n (%)	1 - 5 years	53 (50.5)
	6 - 10 years	14 (13.3)
	More than 10 years	36 (34.3)
	n	105
	Not detectable	83 (79.0)
HIV viral load, n (%)	20 - 200 copies/mL	21 (20.0)
	201 - 1000 copies/mL	1 (1.0)
	n	105
	< 350 cells/mm <sup>3</sup>	6 (5.7)
CD4 T lymphocytes count, n (%)	351 - 500 cells/mm <sup>3</sup>	15 (14.3)
	> 500 cells/mm <sup>3</sup>	84 (80.0)

178 n: number of subjects; HIV: human immunodeficiency virus

179

180 Out of the 105 participants, twenty-one (21.0%) were females. The mean age was 43.35

181 years (s.d:11.69; min 21, max 79 years old), 35.2% and 37.1% had secondary and superior 182 education, respectively, and 43.8% were born outside Portugal. Only two participants had 183 been following ART for less than one year. 79.0% had a non-detectable viral load, and

184 80.0% had a CD4T lymphocyte count higher than 500 cells/mm<sup>3</sup>.

185 The scales used for assessing satisfaction performed well psychometrically: the internal 186 reliability coefficients for HIVTSQs and HIVTSQc were found to be good (alpha = .76 for

187 HIVTSQs; alpha = .88 for HIVTSQc). The correlation between HIVTSQs and HIVTSQc

188 was also significant (rho=.327) (Figure 2).

#### 189 Figure 2. HIVTSQs (and subscales) and HIVTSQc total scores correlations 190 (Spearman correlation)

191

192 As Table 2 shows, the scores of HIVTSOs (at baseline) were not found to be associated 193 with sociodemographic variables or the selected clinical indicators. When considering the 6-194 month assessment (with blister package usage) with HIVTSQc, a significant positive 195 satisfaction evolution was observed (also for the HIVTSQc subscale).

## Tab192. Satisfaction (HIVTSQs and HIVTSQc scores) by sex, age group, education, nationality, and antiretroviral therapy duration

				Sex <sup>2</sup>		1	Age group <sup>2</sup>		1	Education <sup>2</sup>		Ν	Nationality <sup>2</sup>		Antiretroviral therapy duration <sup>2</sup>		
	TOTAL	,1	Female	Male		Less than 50 years	50 years or more		Secondary education or less	Superior education		Portuguese	Non- Portuguese		Up to 5 years	6 years or more	
	N = 105	$\mathbf{p}^1$	n = 22	n = 83	p <sup>2</sup>	n = 69	n = 36	p <sup>2</sup>	n = 66	n = 39	p <sup>2</sup>	n = 59	n = 46	p <sup>2</sup>	n = 55	n = 50	p <sup>2</sup>
HIVTSQs scale																	
Mean (SD)	54.69 (5.52)		55.05 (6.37)	54.59 (5.31)		54.83 (5.82)	54.42 (4.96)		54.64 (6.10)	54.77 (4.46)		53.90 (5.70)	55.70 (5.18)		54.25 (4.99)	55.16 (6.07)	
Median [Q1, Q3]	57.00 (51.00, 59.00)	(a)	57.50 (53.50, 59.75)	57.00 (51.00, 59.00)	0.500	57.00 (51.00, 60.00)	56.00 (51.00, 58.00)	0.361	57.00 (50.25, 59.00)	56.00 (51.00, 59.00)	0.705	56.00 (50.00, 59.00)	57.00 (54.00, 60.00)	0.085	56.00 (50.00, 59.00)	57.00 (53.25, 60.00)	0.19
Minimum - Maximum	37.00 - 60.00		37.00 - 60.00	38.00 - 60.00		37.00 - 60.00	42.00 - 60.00		37.00 - 60.00	47.00 - 60.00		37.00 - 60.00	38.00 - 60.00		43.00 - 60.00	37.00 - 60.00	
HIVTSQs General Satisfacti	ion / Clinical subscale																
Mean (SD) Median [Q1, Q3]	27.78 (2.61) 29.00 (26.00,	(a)	27.59 (2.84) 28.50 (24.75,	27.83 (2.56) 29.00 (26.50,	0.844	28.07 (2.48) 29.00 (27.00,	27.22 (2.78) 28.00 (25.00,	0.116	27.68 (2.81) 28.50 (27.00,	27.95 (2.25) 29.00 (26.00,	0.899	27.31 (2.81) 28.00 (25.00,	28.39 (2.20) 29.00 (28.00,	0.098	27.71 (2.38) 28.00 (27.00,	27.86 (2.86) 29.50 (26.00,	0.292
	30.00)	(a)	30.00)	30.00)	0.644	30.00)	30.00)	0.110	30.00)	30.00)	0.899	30.00)	30.00)	0.098	30.00)	30.00)	0.292
Minimum - Maximum	20.00 - 30.00		22.00 - 30.00	20.00 - 30.00		20.00 - 30.00	21.00 - 30.00		20.00 - 30.00	23.00 - 30.00		21.00 - 30.00	20.00 - 30.00		23.00 - 30.00	20.00 - 30.00	
HIVTSQs Lifestyle/Ease sub																	
Mean (SD)	26.90 (3.52)		27.45 (4.07)	26.76 (3.37)		26.75 (3.76)	27.19 (3.03)		26.95 (3.86)	26.82 (2.88)		26.59 (3.37)	27.30 (3.69)		26.55 (3.33)	27.30 (3.70)	
Median [Q1, Q3]	28.00 (25.00, 30.00)	(a)	29.00 (28.00, 30.00)	28.00 (25.00, 30.00)	0.199	28.00 (25.00, 30.00)	28.00 (25.00, 30.00)	0.890	28.50 (25.00, 30.00)	27.00 (25.00, 30.00)	0.508	28.00 (25.00, 29.00)	29.00 (26.25, 30.00)	0.074	27.00 (25.00, 30.00)	28.50 (27.00, 30.00)	0.14
Minimum - Maximum	15.00 - 30.00		15.00 - 30.00	17.00 - 30.00		15.00 - 30.00	20.00 - 30.00		15.00 - 30.00	20.00 - 30.00		15.00 - 30.00	17.00 - 30.00		17.00 - 30.00	15.00 - 30.00	
HIVTSQc scale	22 21 (0.14)		22.05 (10.27)	22.24 (8.02)		22.07 (7.0()	20.54 (10.00)		21 50 (0.00)	22.21 (0.40)		21.10(10.22)	22 40 (7 40)		22.85 (8.00)	21.45 (10.21)	
Mean (SD)	22.21 (9.14) 25.50 (18.25,		22.05 (10.27) 26.00 (19.00,	22.24 (8.93) 25.00 (18.50,		23.07 (7.96) 26.00 (19.50,	20.54 (10.99) 25.00 (18.00,		21.59 (9.00) 25.00 (18.00,	23.21 (9.40) 28.00 (22.00,		21.19 (10.23) 25.00 (18.00,	23.49 (7.46) 26.00 (19.00,		22.85 (8.06) 26.00 (19.00,	21.45 (10.31) 25.00 (18.50,	
Median [Q1, Q3]	29.00)	< 0.001	28.50)	29.00)	0.853	28.50)	29.00)	0.474	28.00)	29.50)	0.133	28.00)	29.00)	0.368	29.00	28.00)	0.61
Minimum - Maximum	-9 - 30		-6 - 30	-9 - 30		-6 - 30	-9 - 30		-6 - 30	-9 - 30		-9 - 30	0 - 30		0 - 30	-9 - 30	
(NA)	3		3	0		2	1		3	0		2	1		0	3	
HIVTSQc General Satisfacti	ion / Clinical subscale																
Mean (SD)	11.37 (4.74)		12.00 (5.11)	11.23 (4.67)		11.78 (4.21)	10.60 (5.60)		11.21 (4.65)	11.64 (4.93)		10.88 (5.10)	12.00 (4.20)		11.60 (3.99)	11.11 (5.52)	
Median [Q1, Q3]	13.00 (10.00, 15.00)		14.00 (12.00, 15.00)	13.00 (10.00, 15.00)		13.00 (10.50, 15.00)	12.00 (9.00, 15.00)		12.00 (10.00, 15.00)	14.00 (11.00, 15.00)		12.00 (9.00, 15.00)	14.00 (10.00, 15.00)		13.00 (10.50, 15.00)	14.00 (9.50, 15.00)	
Minimum - Maximum	-3 - 15	< 0.001	-3 - 15	-3 - 15	0.299	-3 - 15	-3 - 15	0.611	-3 - 15	-3 - 15	0.397	-3 - 15	0 - 15	0.178	0 - 15	-3 - 15	0.51
(NA)	3		3	0		2	1		3	0		2	1		0	3	
HIVTSOc Lifestyle/Ease sub	oscale																
Mean (SD)	10.83 (4.97)		10.05 (6.11)	11.01 (4.69)		11.30 (4.53)	9.94 (5.68)		10.38 (4.96)	11.56 (4.96)		10.32 (5.35)	11.49 (4.41)		11.25 (4.33)	10.34 (5.63)	
Median [Q1, Q3]	13.00 (9.00, 15.00)	< 0.001	13.00 (8.50, 14.00)	13.00 (9.00, 15.00)	0.621	13.00 (9.00, 15.00)	12.00 (8.50, 14.00)	0.262	12.00 (9.00, 14.00)	14.00 (9.50, 15.00)	0.094	12.00 (9.00, 15.00)	13.00 (9.00, 15.00)	0.375	13.00 (9.00, 15.00)	12.00 (9.00, 14.50)	0.50
Minimum - Maximum	-6 - 15		-3 - 15	-6 - 15		-3 - 15	-6 - 15		-3 - 15	-6 - 15		-6 - 15	-3 - 15		-2 - 15	-6 - 15	
(NA) SD <b>108</b> and Daviations (	3		3	0		2	1		3	0		2	1		0	3	

(NA)
 SD, Standard Deviation; Q1, Quartile 1; Q3, Quartile 3
 1 Witcoom signed rank test for one sample;
 2 Witcoom rank sum test for two independent samples
 (a) Ticoost was not performed for HIVTSQs and respective subscales)
 (NA)
 <li

203 Table 3 also shows that satisfaction with a blister (measured with HIVTSQc) is not predicted by gender, age group, education level, nationality, or ART duration. On the other 204 205 hand, an increase in the baseline treatment satisfaction score was associated with a decrease 206 in the treatment satisfaction change score (six months after the switch to blister). For the 207 HIVTSQc scale model, a one-unit increase in the baseline treatment satisfaction score 208 (HIVTSQs) results in a decrease of 6% [exp (0.06)] in the HIVTSQc overall score.

209

#### 210 Table 3. Satisfaction change (HIVTSQc scores): predictive effect of satisfaction at baseline (HIVTSQs), sociodemografic variables, 211 and clinical variables (linear models)

	HIVTSQc scale				HIVTSQc General Satisfaction / Clinical subscale				HIVTSQc Lifestyle/Ease subscale			
	Model 1		Model 2		Model 1		Model 2		Model 1		Model 2	2
	b (95% CI)	р	b (95% CI)	р	b (95% CI)	р	b (95% CI)	р	b (95% CI)	р	b (95% CI)	р
HIVTSQs*	-0.06 (-0.10; - 0.02)	0.002	-0.06 (-0.10; - 0.02)	0.003	-0.10 (-0.17; - 0.03)	0.006	-0.09 (-0.17; - 0.02)	0.016	-0.09 (-0.15; - 0.04)	0.001	-0.10 (-0.15; - 0.04)	<0.001
Sex												
Female	_	0.000	—		—	0.050	—	0.040	—	0.000	—	0.550
Male	-0.03 (-0.56; 0.51)	0.926	0.08 (-0.47; 0.64)	0.769	0.27 (-0.20; 0.74)	0.252	0.29 (-0.20; 0.78)	0.240	-0.25 (-0.73; 0.23)	0.302	-0.14 (-0.64; 0.35)	0.559
Age group												
Less than 50 years	_						—				—	
50 years or more	0.12 (-0.32; 0.56)	0.591	0.03 (-0.44; 0.49)		0.02 (-0.37; 0.41)	0.918 0.0	0.02 (-0.39; 0.44)	0.914	0.26 (-0.12; 0.65)	0.178	0.17 (-0.23; 0.57)	0.409
Education												
Secondary education or less	_	0.114	_	0.102	_	0.400	_	0.200	_	0.070	_	0.174
Superior education	-0.34 (-0.76; 0.08)	0.114	-0.31 (-0.76; 0.15)	0.183	-0.13 (-0.51; 0.25)	0.498	-0.17 (-0.57; 0.23)	0.390	-0.36 (-0.73; 0.01)	0.060	-0.27 (-0.67; 0.12)	0.174
Nationality												
Portuguese	_		_		_		_		_		_	
Non-Portuguese	-0.10 (-0.52; 0.33)	0.655	-0.07 (-0.50; 0.35)	0.735	-0.16 (-0.54; 0.21)	0.388	-0.16 (-0.54; 0.23)	0.420	-0.15 (-0.52; 0.23)	0.435	-0.11 (-0.49; 0.26)	0.549
Antiretroviral therapy duration												
Up to 5 years	—		—		_		—				—	
6 years or more	0.21 (-0.21; 0.62)	0.331	0.14 (-0.31; 0.59)	0.541	-0.08 (-0.45; 0.29)	0.670	-0.08 (-0.48; 0.32)	0.705	0.24 (-0.13; 0.61)	0.207	0.11 (-0.28; 0.51)	0.574

CI, Confidence Interval

\* These coefficients report to scores in HIVTSQs scale, HIVTSQs General Satisfaction / Clinical subscale and HIVTSQs Lifestyle/Ease subscale in models for HIVTSQc scale, HIVTSQc

General Satisfaction / Clinical subscale and HIVTSQc Lifestyle/Ease subscale, respectively. For analysis, HIVTSQc scores were shifted, reversed and log transformed.

Model 1, Individual models adjusted for each variable presented, plus the HIVTSQs score

212 213 214 215 216 Model 2, Model adjusted for all the variables presented

218 This predictive value of baseline satisfaction (HIVTSQs) was also observed for the 219 HIVTSOc subscale (general satisfaction/clinical subscale).

220 Plots in Figure 2 provide some insight into the facets of blister packaging, as perceived by 221 patients (compared with bottles) that may support the observed positive evolution of 222 satisfaction. Although no significant difference was found in the proportion of patients 223 reporting appreciating positively the packaging (bottle and blister), three main facets of 224 usage were found to be better considered by patients: a significantly higher proportion of 225 them considered that the blister helps them to keep track of daily intake of pills; a higher 226 proportion indicate that blister packaging usage is more discrete than bottle usage; and a 227 higher proportion report that blister packaging helps them to recall the refill momentum.

228

229 Figure 3. Frequencies of item response on the specifically developed questionnaire between 230 packaging methods 231

232 Overall, and as seen in Figure 3, 68.6% of patients report being more satisfied with the 233 blister packaging than with bottle packaging. 234

#### 235 Figure 4. Response distribution on patients' satisfaction with blister packaging, when 236 compared with bottle packaging

- 238 Regarding adherence, no significant differences were observed between the standard pill 239 bottle and monthly blister packaging: 89.7% and 91.3% of adherence, respectively.
- 240

237

#### Discussion 241

242 Main aim of this project was to assess if introducing a new packaging would affect 243 satisfaction and adherence with ART. The study was planned as a two-center, observational 244 retrospective and prospective study with 18+ years old PLHIV conducted in Portuguese 245 hospitals (non-random sampling). The bottle effect was assessed retrospectively for at least 246 six months, and the blister effect was prospectively evaluated for a period of at least six 247 months of usage. Overall, 105 PLHIV were enrolled and 102 completed the prospective 248 component of the study.

- 249 The main outcome of the study was satisfaction with ART treatment. Patients reported an
- 250 increase in satisfaction with the Biktarvy<sup>®</sup> blister packaging (compared with previous bottle 251 packaging). And this increase in satisfaction was independent of several main 252 sociodemographic and clinical characteristics. Importantly, the patients who became more 253 satisfied with ART treatment (when using blister packaging) were the least satisfied with
- 254 bottle packaging.
- 255 Another main finding regards the perception of utility from the blister packaging: after a 256 minimum of six month of experience, the blister (which includes a weekly calendar) was
- 257 considered by the majority (85%) of patients as an effective tool to keep track of their daily
- 258 intake of pills (significant higher percentage than the appreciation for bottle packaging),
- 259 and about two third of patients considered that it is helpful as a reminder of the adequate
- 260 moment of refilling.
- 261

#### Conclusion 262

- 263 To our knowledge this is the first study evaluating satisfaction with blister calendar package
- usage of ART by PLHIV, and the same for medication packaging in blister packs with a
   weekly calendar for the treatment of different diseases.
- 266 Overall, these findings support the advantages of the new packaging. Nevertheless,
- adherence was not found to be significantly higher for blister than for bottle packaging
- 268 (though with a slight increase of proportion in adherence: 1.6 percentual points). This
- 269 issue calls for future research, also because the lapse of time after introducing the new
- 270 packaging was limited (about six months). Larger samples, including selected populations
- with more extended periods of blister utilization, may provide sounder evidence about the
- adherence potential of this Biktarvy<sup>®</sup> new packaging.

## 273

#### Acknowledgments 274

- The authors thank the patients who accepted to participate in the study, Prof. Clare Bradley 275
- 276 and Health Psychology Research Limited (HPR) for the HIVTSQs and HIVTSQc, and Ana
- 277 Sequeira and Hugo Caldeira for technical assistance.
- 278

#### **Conflict of interests** 279

280 The authors declare no conflict of interest, except for Maria Pinto da Silva who is an

- 281 employee of Gilead Sciences, Lda., Lisboa, Portugal, and owns shares in Gilead.
- 282

#### Supporting information captions 283

- 284 Figure 1. Study design diagram
- 285 Table 1. Sociodemographic and clinical characteristics of the participants
- 286 Figure 2. HIVTSQs (and subscales) and HIVTSQc total scores correlations (Spearman 287 correlation)
- 288 Table 2. Satisfaction (HIVTSQs and HIVTSQc scores) by sex, age group, education, 289 nationality, and antiretroviral therapy duration
- 290 Table 3. Satisfaction change (HIVTSQc scores): predictive effect of satisfaction at baseline
- 291 (HIVTSQs), sociodemografic variables, and clinical variables (linear models)
- 292 Figure 3. Frequencies of item response on the specifically developed questionnaire between 293 packaging methods
- 294 Figure 4. Response distribution on patients' satisfaction with blister packaging, when 295 compared with bottle packaging
- 296

#### References 297

298 299

300

301

- 1. EACS Guidelines version 12.0, October 2023.
- 2. Paramesha AE, Chacko LK. Predictors of adherence to antiretroviral therapy among PLHIV. Indian J Public Health. 2019;63(4):367-76.
- 302 3. Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, Quirk E. Patient-303 reported symptoms over 48 weeks among participants in randomized, double-blind, 304 phase III non- inferiority trials of adults with HIV on co-formulated bictegravir, 305 emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, 306 dolutegravir, and lamivudine. Patient. 2018;11(5):561-73.
- 307 4. Curran A, Arends J, Buhk T, Cascio M, Teofilo E, van den Berk G, Guaraldi G. 308 "Moving Fourth": Introduction of a practical toolkit for shared decision-making to 309 facilitate healthy living beyond HIV viral suppression. AIDS Rev. 2021;23(4):204-310 13.
- 311 5. Schneider PJ, Murphy JE, Pedersen CA. Impact of medication packaging on 312 adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc 313 (2003). 2008;48(1):58-63.
- 314 6. Conn VS, Ruppar TM, Chan KC, Dunbar-Jacob J, Pepper GA, De Geest S. 315 Packaging interventions to increase medication adherence: systematic review and 316 meta-analysis. Curr Med Res Opin. 2015;31(1):145-60.


- 317 7. Biktarvy Summary of Product Characteristics, May 2021.
- 8. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. *Value Health*. 2006;9(5): 320-33.
- 321 9. Serrão R, Mansinho K, Maltez F, Marques N, Carvalho A, Pazos R, et al. Real322 World characterization of the portuguese population living with HIV who initiated
  323 raltegravir based-regimens: The REALITY Study. Acta Med Port. 2022;35(7324 8):558-65.

	First	Later
Delivery of	delivery of	delivery of
Biktarvy <sup>®</sup>	Biktarvy®	Biktarvy®
bottles	monthly	monthly
	blisters	blisters


Retrospective assessment for satisfaction: Biktarvy <sup>®</sup> bottle for at least 6 months		Prospective assessment for satisfaction: <u>Biktarvy</u> <sup>®</sup> blister for at least 6 months	
Pharmacy records collected on adherence: Total tablets (= prior + delivered - remaining) Total days since last pick-up		Pharmacy records collected on adherence: Total tablets (= prior + delivered – remaining) Total days since last pick-up	
	<u>Time 0</u> : participants fill in HIVTSQs		<u>Time 1</u> : participants fill in HIVTSQc

	HIVTSQs scale	HIVTSQs General Satisfaction / Clinical subscale	HIVTSQs Lifestyle/Ease subscale	HIVTSQc scale	HIVTSQc General Satisfaction / Clinical subscale	HIVTSQc Lifestyle/Ease subscale	
40 - 30 - 20 - 10 -	medRxiv preprint doi: https://di preprint (which was not cerf	oi.org/10.1101/2024.10.26.24316182; th i <b>fied by peer review)</b> is the author/func perpetui It is made available under a CC-E	is version posted October 27, 2024. ler, who has granted medRxiv a licer ty. Y 4.0 International license .	The copyright holder for this use to display the preprint in 0.327***	Corr: 0.310**	Corr: 0.329***	HIVTSQs scale
30.0 - 27.5 - 25.0 - 22.5 - 20.0 -			Corr: 0.629***	Corr: 0.257**	Corr: 0.268**	Corr: 0.232*	HIVTSQs General Satisfaction / Clinical subscale
30 - 25 - 20 - 15 -				Corr: 0.292**	Corr: 0.252*	Corr: 0.332***	HIVTSQs Lifestyle/Ease subscale
30 - 20 - 10 - 0 -					Corr: 0.864***	Corr: 0.911***	HIVTSQc scale
15 - 10 - 5 - 0 -						Corr: 0.636***	HIVTSQc General Satisfaction / Clinical subscale
15 - 10 - 5 - 0 - -5 -		20.022.525.027.530.0	15 20 25 30-	10 0 10 20 30	0 5 10 15		HIVTSQc Lifestyle/Ease subscale







## This packaging reminds me that I need to refill my prescription




## This packaging lets me take the pill easily and discreetly



## I don't like this packaging



## I am more satisfied with this packaging than with the previous one



Percentage